XXXX AND @entity2493 AGONISTS AS ADJUNCTIVE TREATMENTS IN BIPOLAR DISORDERS.

@entity1 @entity162 @entity146 @entity17508 @entity2438 @entity2493 @entity74 @entity209 @entity25 @entity22
UNASSIGNED: @entity162 ( @entity162 ) present with abnormalities of circadian rhythmicity and sleep homeostasis, even during phases of remission. These abnormalities are linked to the underlying neurobiology of and genetic susceptibility to @entity162 . @entity2493 is a pineal gland secreted neurohormone that induces circadian-related and sleep-related responses. Exogenous @entity2493 has demonstrated efficacy in treating @entity22 , delayed sleep @entity74 , improving sleep parameters and overall sleep quality, and some @entity146 disorders like @entity2438 . In order to evaluate the efficacy of @entity2493 among @entity1 with @entity162 , this comprehensive review emphasizes the abnormal @entity2493 function in @entity162 , the rationale of @entity2493 action in @entity162 , the available data about the exogenous administration of @entity2493 , and @entity2493 agonists (ramelteon and @entity17508 ), and recommendations of use in @entity1 with @entity162 . There is a scientific rationale to propose @entity2493 -agonists as an adjunctive treatment of mood stabilizers in treating @entity25 in @entity162 and thus to possibly prevent relapses when administered during remission phases. We emphasized the need to treat @entity22 , sleep delayed latencies and @entity25 in @entity162 are prodromal markers of an emerging mood episode and possible targets to prevent future relapses. An additional interesting adjunctive therapeutic effect might be on preventing @entity209 , particularly in @entity1 treated with antipsychotics. Finally, @entity2493 is well tolerated and has little dependence potential in contrast to most available sleep medications. Future studies are expected to be able to produce stronger evidence-based therapeutic guidelines to confirm and delineate the routine use of @entity2493 -agonists in the treatment of @entity162 .
